A systematic review of adult admissions to ICUs related to adverse drug events

Critical Care

Volumn 18, Issue 6, 2014, Pages

  Jolivot, Pierre Alain ^a,b,c   Hindlet, Patrick ^a,b,c,d   Pichereau, Claire ^c   Fernandez, Christine ^a,b,c,d   Maury, Eric ^a,b,c   Guidet, Bertrand ^a,b,c   Hejblum, Gilles ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; DISEASE SEVERITY; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORTALITY; NOMENCLATURE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; TRENDS;

ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INTENSIVE CARE UNITS; PATIENT ADMISSION;

EID: 84927737485     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0643-5     Document Type: Review

References (36)

1. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008, 42:1017-1025. 10.1345/aph.1L037, 18594048.
2. Evans TW, Nava S, Mata GV, Guidet B, Estenssoro E, Fowler R, Scheunemann LP, White D, Manthous CA. Critical care rationing: international comparisons. Chest 2011, 140:1618-1624. 10.1378/chest.11-0957, 22147820.
3. Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, Moreno RP. The variability of critical care bed numbers in Europe. Intensive Care Med 2012, 38:1647-1653. 10.1007/s00134-012-2627-8, 22777516.
4. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician?s guide to terminology, documentation, and reporting. Ann Intern Med 2004, 140:795-801. 10.7326/0003-4819-140-10-200405180-00017, 15148066.
5. The Importance of Pharmacovigilance. Safety Monitoring of Medicinal Products. In []., http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf
6. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems. In []., http://www.who.int/patientsafety/events/05/Reporting_Guidelines.pdf
7. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4:e297. 10.1371/journal.pmed.0040297, 17941715.
8. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700. 10.1136/bmj.b2700, 19622552.
9. Schwarzer G. meta: an R package for meta-analysis. R News 2007, 7:40-45.
10. Trunet P, Borda IT, Rouget AV, Rapin M, Lhoste F. The role of drug-induced illness in admissions to an intensive care unit. Intensive Care Med 1986, 12:43-46. 10.1007/BF00315371, 3711425.
11. Epidemiology of adverse drug reactions in intensive care units: a multicentre prospective survey. Eur J Clin Pharmacol 1987, 31:507-512. 10.1007/BF00606621.
12. Nelson KM, Talbert RL. Drug-related hospital admissions. Pharmacotherapy 1996, 16:701-707. 8840382.
13. Darchy B, Le Miere E, Figueredo B, Bavoux E, Domart Y. Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med 1999, 159:71-78. 10.1001/archinte.159.1.71, 9892333.
14. Hammerman H, Kapeliovich M. Drug-related cardiac iatrogenic illness as the cause for admission to the intensive cardiac care unit. Isr Med Assoc J 2000, 2:577-579. 10979347.
15. Lehmann LS, Puopolo AL, Shaykevich S, Brennan TA. Iatrogenic events resulting in intensive care admission: frequency, cause, and disclosure to patients and institutions. Am J Med 2005, 118:409-413. 10.1016/j.amjmed.2005.01.012, 15808139.
16. Grenouillet-Delacre M, Verdoux H, Moore N, Haramburu F, Miremont-Salame G, Etienne G, Robinson P, Gruson D, Hilbert G, Gabinski C, Begaud B, Molimard M. Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital. Intensive Care Med 2007, 33:2150-2157. 10.1007/s00134-007-0787-8, 17653528.
17. Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 2007, 64:1840-1843. 10.2146/ajhp060641, 17724366.
18. Schwake L, Wollenschlager I, Stremmel W, Encke J. Adverse drug reactions and deliberate self-poisoning as cause of admission to the intensive care unit: a 1-year prospective observational cohort study. Intensive Care Med 2009, 35:266-274. 10.1007/s00134-008-1250-1, 18696050.
19. Mercier E, Giraudeau B, Ginies G, Perrotin D, Dequin PF. Iatrogenic events contributing to ICU admission: a prospective study. Intensive Care Med 2010, 36:1033-1037. 10.1007/s00134-010-1793-9, 20217046.
20. Nazer LH, Eljaber R, Rimawi D, Hawari FI. Adverse drug events resulting in admission to the intensive care unit in oncology patients: incidence, characteristics and associated cost. J Oncol Pharm Pract 2013, 19:298-304. 10.1177/1078155212465995, 23223402.
21. Trunet P, Le Gall JR, Lhoste F, Regnier B, Saillard Y, Carlet J, Rapin M. The role of iatrogenic disease in admissions to intensive care. JAMA 1980, 244:2617-2620. 10.1001/jama.1980.03310230019015, 7431607.
22. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, Vander Vliet M, Nemeskal R, Leape LL. Incidence of adverse drug events and potential adverse drug events: implications for prevention ADE Prevention Study Group. JAMA 1995, 274:29-34. 10.1001/jama.1995.03530010043033, 7791255.
23. Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol 2001, 28:1180-1187. 11361210.
24. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992, 27:538. 10118597.
25. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979, 242:623-632. 10.1001/jama.1979.03300070019017, 449002.
26. The Use of the WHO-UMC System for Standardised Case Causality Assessment. In []., http://www.who-umc.org/Graphics/26649.pdf
27. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245. 10.1038/clpt.1981.154, 7249508.
28. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977, 21:247-254. 837643.
29. Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, Damsbo N. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990, 228:83-90. 10.1111/j.1365-2796.1990.tb00199.x, 2394974.
30. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs: Actualization of the method used in France. Therapie 1985, 40:111-118. 4002188.
31. Vlayen A, Verelst S, Bekkering GE, Schrooten W, Hellings J, Claes N. Incidence and preventability of adverse events requiring intensive care admission: a systematic review. J Eval Clin Pract 2012, 18:485-497. 10.1111/j.1365-2753.2010.01612.x, 21210898.
32. Hakkarainen KM, Andersson Sundell K, Petzold M, Hagg S. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf 2012, 35:105-126. 10.2165/11596570-000000000-00000, 22201475.
33. Kane-Gill SL, Forsberg EA, Verrico MM, Handler SM. Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs. Drug Saf 2012, 35:645-653. 10.1007/BF03261961, 22720659.
34. Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, Leverve X, Lapostolle F, Borron SW, Adnet F. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf 2007, 30:81-88. 10.2165/00002018-200730010-00008, 17194173.
35. Trinh-Duc A, Doucet J, Bannwarth B, Trombert-Paviot B, Carpentier F, Bouget J, Queneau P. Admissions of elderly to French emergency departments related to adverse drug events. Therapie 2007, 62:437-441. 10.2515/therapie:2007063, 18206105.
36. Chen YC, Fan JS, Hsu TF, Chen MH, Huang HH, Cheng KW, Yen DH, Huang MS, Lee CH, Chen LK, Yang CC. Detection of patients presenting with adverse drug events in the emergency department. Intern Med J 2012, 42:651-657. 10.1111/j.1445-5994.2011.02684.x, 22188441.